KR20220004111A - 신장질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 - Google Patents

신장질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 Download PDF

Info

Publication number
KR20220004111A
KR20220004111A KR1020217038004A KR20217038004A KR20220004111A KR 20220004111 A KR20220004111 A KR 20220004111A KR 1020217038004 A KR1020217038004 A KR 1020217038004A KR 20217038004 A KR20217038004 A KR 20217038004A KR 20220004111 A KR20220004111 A KR 20220004111A
Authority
KR
South Korea
Prior art keywords
compound
present
acid
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217038004A
Other languages
English (en)
Korean (ko)
Inventor
카트자 엘스 콘라스
레지널드 크리스토퍼 사비에르 브리시
티에리 진-클라우드 마리 크리스토페
로날드 반 더 지스트
Original Assignee
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈라파고스 엔.브이. filed Critical 갈라파고스 엔.브이.
Publication of KR20220004111A publication Critical patent/KR20220004111A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217038004A 2019-04-24 2020-04-21 신장질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 Withdrawn KR20220004111A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
GB1905711.6 2019-04-24
PCT/EP2020/061083 WO2020216740A1 (en) 2019-04-24 2020-04-21 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (1)

Publication Number Publication Date
KR20220004111A true KR20220004111A (ko) 2022-01-11

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038004A Withdrawn KR20220004111A (ko) 2019-04-24 2020-04-21 신장질환의 치료를 위한 신규 화합물 및 그의 약학 조성물

Country Status (16)

Country Link
US (1) US12383544B2 (https=)
EP (1) EP3958863B1 (https=)
JP (1) JP7543304B2 (https=)
KR (1) KR20220004111A (https=)
CN (1) CN113727711A (https=)
AU (1) AU2020263869A1 (https=)
BR (1) BR112021021117A2 (https=)
CA (1) CA3137445A1 (https=)
ES (1) ES2982398T3 (https=)
GB (1) GB201905711D0 (https=)
IL (1) IL287392A (https=)
MA (1) MA55752A (https=)
MX (1) MX2021012544A (https=)
PH (1) PH12021552680A1 (https=)
SG (1) SG11202111739VA (https=)
WO (1) WO2020216740A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096453A1 (en) * 2023-10-30 2025-05-08 Vertex Pharmaceuticals Incorporated Compounds for the treatment of kidney disease
WO2025121320A1 (ja) * 2023-12-04 2025-06-12 国立大学法人山口大学 多発性嚢胞腎の予防又は治療剤
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥（香港）有限公司 用於治療體染色體顯性多囊性腎病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP2464354B1 (en) * 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
TWI704919B (zh) * 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
US10174012B2 (en) * 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
US10130622B2 (en) * 2015-10-09 2018-11-20 Abbvie S.Á.R.L. Compounds for treatment of cystic fibrosis
AU2016333855A1 (en) 2015-10-09 2018-04-26 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
WO2018237174A2 (en) * 2017-06-21 2018-12-27 The Johns Hopkins University CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS

Also Published As

Publication number Publication date
IL287392A (en) 2021-12-01
SG11202111739VA (en) 2021-11-29
MX2021012544A (es) 2021-11-12
MA55752A (fr) 2022-03-02
AU2020263869A1 (en) 2021-12-23
GB201905711D0 (en) 2019-06-05
EP3958863B1 (en) 2024-07-03
CA3137445A1 (en) 2020-10-29
WO2020216740A1 (en) 2020-10-29
CN113727711A (zh) 2021-11-30
US20220202802A1 (en) 2022-06-30
EP3958863C0 (en) 2024-07-03
PH12021552680A1 (en) 2022-07-04
JP7543304B2 (ja) 2024-09-02
BR112021021117A2 (pt) 2021-12-14
US12383544B2 (en) 2025-08-12
EP3958863A1 (en) 2022-03-02
ES2982398T3 (es) 2024-10-16
JP2022529814A (ja) 2022-06-24

Similar Documents

Publication Publication Date Title
EP3517538B1 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
CA2974853C (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
AU2020378407B2 (en) Heterocyclic RIP1 inhibitory compounds
US10752653B2 (en) Oxysterols and methods of use thereof
ES2791186T3 (es) Triazoles como inhibidores de receptores NR2B
AU2014204831C1 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
EP3027614A1 (de) Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen
JPWO2007102531A1 (ja) 併用薬
EA016234B1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
KR102805250B1 (ko) Mtorc1 조절제 및 이의 용도
US12383544B2 (en) Methods for the treatment of polycystic kidney disease
KR102723164B1 (ko) 피라졸로[1,5-a]피리미딘 화합물의 염 및 이의 결정
KR101905295B1 (ko) 나프티리딘디온 유도체
AU2015317886A1 (en) Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
EA017117B1 (ru) 2-АМИНО-3-СУЛЬФОНИЛТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИДОПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT-РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA3071074A1 (en) New propanamine derivatives for treating pain and pain related conditions
EP3700890B1 (en) Alcoxyamino derivatives for treating pain and pain related conditions
EP2729471B1 (de) Carbonsäurederivate mit einem oxazolo[5,4-d]pyrimidinring
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
EA017817B1 (ru) 3-АРИЛСУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN106795160A (zh) 取代的吲哚化合物及其使用方法和用途
AU1401600A (en) Novel type condensed pyridazinone compounds
KR100742134B1 (ko) 결정성Ｓ-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-ｃ]피리딘-5(4Ｈ)-일)아세테이트·캄실레이트를 포함하는약학적 조성물
WO2015193229A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203